Pocapavir

Antiviral drug

Pocapavir
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Pocapavir (also known by its research code V-073) is an antiviral drug that has been investigated for its potential use in treating infections caused by poliovirus. It is a member of the class of drugs known as capsid inhibitors, which work by interfering with the viral capsid, thereby preventing the virus from successfully replicating within host cells.

Mechanism of Action

Pocapavir functions by binding to the viral capsid of poliovirus. The capsid is the protein shell of a virus, which encases its genetic material. By binding to the capsid, Pocapavir stabilizes it and prevents the uncoating process that is necessary for the viral RNA to be released into the host cell. This inhibition of uncoating effectively halts the replication cycle of the virus, thereby reducing viral load and limiting the spread of infection.

Clinical Development

Pocapavir has been studied in various clinical trials to assess its efficacy and safety in humans. These studies have primarily focused on its use in treating poliovirus infections, particularly in cases where the virus is resistant to vaccines or in immunocompromised individuals who cannot receive live vaccines. The drug has shown promise in reducing viral shedding and shortening the duration of infection.

Potential Applications

While Pocapavir is primarily targeted at poliovirus, its mechanism of action suggests potential utility against other enteroviruses, which share similar structural characteristics. Research is ongoing to explore its effectiveness against a broader range of viral infections.

Safety and Side Effects

As with any antiviral medication, the safety profile of Pocapavir is a critical consideration. Clinical trials have reported some side effects, which are generally mild and include gastrointestinal disturbances and headaches. However, further studies are needed to fully understand the long-term safety implications of Pocapavir use.

Regulatory Status

As of the latest updates, Pocapavir has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for widespread clinical use. It remains an investigational drug, primarily used in controlled clinical settings.

Research and Future Directions

Ongoing research is focused on optimizing the formulation of Pocapavir to enhance its bioavailability and therapeutic efficacy. Additionally, studies are being conducted to evaluate its potential role in combination therapies with other antiviral agents to improve outcomes in poliovirus and other enterovirus infections.

Related Pages

• Poliovirus
• Antiviral drug
• Capsid inhibitor
• Enterovirus